Skip to content
Screener

Metagenomi Therapeutics, Inc. MGX Q2 2026 earnings

Reported August 10, 2026 · After market close

Revenue-$257.0KMiss by $3.3M
EPS-$0.73Miss by $0.18
Revenue estimate$3.0M
EPS estimate-$0.55

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$2.6M
EPS estimate-$0.64

FAQ

When did Metagenomi Therapeutics, Inc. report Q2 2026 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q2 2026 earnings on August 10, 2026 after market close.
What were Metagenomi Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of -$257.0K and eps of $-0.73 for Q2 2026.
Did Metagenomi Therapeutics, Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $3.0M by $3.3M. EPS missed the consensus estimate of $-0.55 by $0.18.
How did Metagenomi Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 103.0% from $8.5M a year earlier and eps declined 35.2% from $-0.54.
Where can I find Metagenomi Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-342388) and the 10-Q periodic report (0001193125-26-342400) directly on SEC EDGAR. The filing index links above go to sec.gov.